BRCA1 expression exploratory analysis in patients of the phase III trial of trabectedin vs. doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

被引：0
|
作者：
Aracil, M. [1 ]
Lardelli, P. [2 ]
Nieto, A. [2 ]
Galmarini, C. M. [1 ]
机构：
[1] PharmaMar SA, R&D, Colmenar Viejo, Madrid, Spain
[2] PharmaMar SA, Clin Dev, Colmenar Viejo, Madrid, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70161-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
35
引用
收藏
页码：17 / 17
页数：1
相关论文
共 50 条
  • [1] Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas
    Blay, Jean-Yves
    Leahy, Michael G.
    Binh Bui Nguyen
    Patel, Shreyaskumar R.
    Hohenberger, Peter
    Santoro, Armando
    Staddon, Arthur P.
    Penel, Nicolas
    Piperno-Neumann, Sophie
    Hendifar, Andrew
    Lardelli, Pilar
    Nieto, Antonio
    Alfaro, Vicente
    Chawla, Sant P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (06) : 1137 - 1147
  • [2] Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS).
    Blay, Jean-Yves
    Leahy, Michael Gordon
    Binh Bui Nguyen
    Patel, Shreyaskumar
    Santoro, Armando
    Hohenberger, Peter
    Demetri, George D.
    Lardelli, Pilar
    Perez, Iratxe
    Chawla, Sant P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Safety of trabectedin versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients with translocation-related sarcoma (TRS)
    Chawla, S. P.
    Italiano, A.
    Patel, S.
    Hohenberger, P.
    Santoro, A.
    Staddon, A. P.
    Lardelli, P.
    Gomez, J.
    Kahatt, C.
    Blay, J. Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S885 - S885
  • [4] Results of the randomized phase III trial of trabectedin (F) versus doxorubicin-based chemotherapy (DXCT) as First-line therapy in patients (pts) with translocation-related sarcoma (TRS).
    Hendifar, Andrew Eugene
    Chawla, Sant P.
    Leahy, Michael Gordon
    Italiano, Antoine
    Patel, Shreyaskumar
    Santoro, Armando
    Staddon, Arthur P.
    Penel, Nicolas
    Piperno-Neumann, Sophie
    Demetri, George D.
    Hayward, Larry
    White, Jeff
    Gouw, Launce G.
    De Miguel, Bernardo
    Lardelli, Pilar
    Soto, Arturo
    Nieto, Antonio
    Blay, Jean-Yves
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Results of a multivariate analysis for potential factors affecting outcome in translocation related sarcomas (TRS) treated with trabectedin or doxorubicin-based chemotherapy (DXCT) as first-line therapy
    Chawla, S. P.
    Leahy, M. G.
    Italiano, A.
    Patel, S.
    Penel, N.
    Piperno-Neumann, S.
    Lardelli, P.
    Soto-Matos, A.
    Nieto, A.
    Blay, J. Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S885 - S885
  • [6] Randomized phase II trial of doxorubicin vs. trabectedin plus doxorubicin in first line treatment of patients with advanced non-resectable or metastatic soft tissue sarcomas: a Spanish Group for Sarcoma Research (GEIS) study
    Martin-Broto, J.
    Lopez-Pousa, A.
    Garcia del Muro, X.
    De Las Penas, R.
    Martinez-Trufero, J.
    Cruz, J.
    Alvarez, R.
    Cubedo, R.
    Redondo, A.
    Poveda, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S875 - S875
  • [7] Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
    Ku, Geoffrey Y.
    Haaland, Benjamin A.
    Lopes, Gilberto de Lima, Jr.
    [J]. LUNG CANCER, 2011, 74 (03) : 469 - 473
  • [8] RANDOMIZED, OPEN, PROSPECTIVE, PHASE II CLINICAL TRIAL OF DOXORUBICIN (DOXO) VS. TRABECTEDIN PLUS DOXO IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED NON-OPERABLE AND/OR METASTATIC SOFT TISSUE SARCOMAS (STS): GEIS-20 STUDY
    Martin Broto, J.
    Garcia Del Muro, X.
    Lopez-Pousa, A.
    De Las Penas, R.
    Maurel, J.
    Cubedo, R.
    Redondo, A.
    Martinez-Trufero, J.
    Cruz Jurado, J.
    Poveda, A. M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 490 - 490
  • [9] Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer phase III POLO trial
    Golan, T.
    Hammel, P.
    Reni, M.
    Van Cutsen, E.
    Macarulla, T.
    Hall, M.
    Park, J.
    Hochhauser, D.
    Arnold, D.
    Oh, D.
    Reinacher-Shick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, E.
    McGuinness, D.
    Cui, K.
    Schlienger, K.
    Locker, G.
    Kindler, H.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [10] Overall survival analysis from a randomised phase III trial of axitinib vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma
    Hutson, T. E.
    Al-Shukri, S.
    Stus, V. P.
    Lipatov, O. N.
    Shparyk, Y.
    Bair, A. H.
    Rosbrook, B.
    Andrews, G. I.
    Vogelzang, N. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S476 - S477
12345